Godown Justin, Deal Allison M, Riley Kathy, Bailliard Frederique, Blatt Julie
J Pediatr Pharmacol Ther. 2011 Jul;16(3):218-21. doi: 10.5863/1551-6776-16.3.218.
Immunosuppressive regimens, which include antithymocyte globulin (ATG), are widely used for the treatment of severe aplastic anemia (SAA). However, bradycardia has been reported only as a rare side effect of ATG therapy in the manufacturer's product information and, in rare cases, in the adult literature. We present an adolescent with SAA and preexisting bradycardia who underwent immunosuppression therapy with ATG, methylprednisolone, and tacrolimus and developed profound sinus bradycardia with successive doses of ATG.
包括抗胸腺细胞球蛋白(ATG)在内的免疫抑制方案被广泛用于治疗重型再生障碍性贫血(SAA)。然而,心动过缓仅在制造商的产品信息中被报告为ATG治疗的罕见副作用,在成人文献中也有罕见病例报道。我们报告一名患有SAA且既往有心动过缓的青少年,其接受了ATG、甲泼尼龙和他克莫司的免疫抑制治疗,并在连续使用ATG后出现了严重的窦性心动过缓。